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Ceftazidime is (Z)-(7R)-7-[2-(2-aminothiazol-4-yl)-2-(1-carboxy-1-methoxyimino)ace-
tamido]-3-(1-pyridiniomethyl)-3-cephem-4-carboxylate pentahydrate (CFZM) (1, 2). It is
a third generation cephalosporin antibiotic characterized by a broad antibacterial spec-
trum and resistant to beta-lactamase producing organisms in addition to its antimicro-
bial activity against Streptococci, Staphylococci, Pneumococci, etc. Several analytical proce-
dures are available in the literature for the analysis of ceftazidime, via high performance
liquid chromatography (4–7), charge transfer complexation (8), and spectrophotometric
methods (9–14). Most of the spectrophotometric methods reported earlier suffer from di-
sadvantages like a narrow linearity range, requiring heating or extraction, long time for
the reaction to complete, use of non-aqueous systems, low stability of the colored prod-
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Two spectrophotometric methods for the determination
of ceftazidime (CFZM) in either pure form or in its phar-
maceutical formulations are described. The first method
is based on the reaction of 3-methylbenzothiazolin-2-one
hydrazone (MBTH) with ceftazidime in the presence of
ferric chloride in acidic medium. The resulting blue com-
plex absorbs at lmax 628 nm. The second method descri-
bes the reaction between the diazotized drug and N-(1-
-naphthyl)ethylenediamine dihydrochloride (NEDA) to
yield a purple colored product with lmax at 567 nm. The
reaction conditions were optimized to obtain maximum
color intensity. The absorbance was found to increase li-
nearly with increasing the concentration of CFZM; the sys-
tems obeyed the Beer’s law in the range 2–10 and 10–50
µg mL–1 for MBTH and NEDA methods, resp. LOD, LOQ
and correlation coefficient values were 0.15, 0.79 and
0.50, 2.61. No interference was observed from common
excipients present in pharmaceutical formulations. The
proposed methods are simple, sensitive, accurate and
suitable for quality control applications.
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uct formed. In continuation of our research on spectrophotometric determination of or-
ganic compounds of pharmaceutical importance (15, 16), the present communication re-
ports two spectrophotometric methods for the determination of ceftazidime in either




An ELICO Model SL-164 double beam, UV-VIS spectrophotometer (Elico India Ltd.,
India) with 1.0 cm matched quartz cells was used for absorbance measurements.
Reagents and materials
Ceftazidime (gift sample from Alkem Laboratories Ltd., India), 3-methylbenzothia-
zolin-2-one hydrazone (MBTH) (Himedia Laboratories Pvt. Ltd., India, certified to be
99.0%) and N-(1-naphthyl)ethylenediamine dihydrochloride (NEDA) (S. d. Fine Chem.,
India, certified to be 98.5%) were used. All other chemicals and solvents used were of
analytical reagent grade.
The following dosage forms containing ceftazidime were purchased from local com-
mercial sources: 1 – Tazid injections equivalent to 250 mg ceftazidime (Alkem Labora-
tories Ltd., India), 2 – Tizime injections equivalent to 500 mg (Lupin Laboratories Ltd.)
and 3 – Cefazid injections equivalent to 1000 mg (Biochem Pharmaceutical Inds., India).
Standard solutions
A stock solution of ceftazidime (1 mg mL–1) in water was kept in dark to avoid drug
degradation. The working standard solution of ceftazidime containing 100 mg mL–1 was
prepared by dilution.
Aqueous solutions (0.2%) of MBTH (8.6 ´10–3 mol L–1) and NEDA (8 ´ 10–3 mol L–1)
were freshly prepared.
Analytical procedures
Method I (MBTH method). – Aliquots of the working standard solution of the drug
(0.2–1.0 mL) (100 mg mL–1) were transferred into 10-mL calibrated flasks. To each aque-
ous solution of FeCl3 (1.5 mL, 3 ´ 10–2 mol L–1), an aqueous solution of MBTH (1.0 mL,
8.6 ´ 10–3 mol L–1) was added. The solutions were swirled and allowed to stand for 5
min. Then hydrochloric acid (1.0 mL, 1 ´ 10–2 mol L–1) was added and made up to the
mark with water. The absorbance was measured at 628 nm against the corresponding re-
agent blank and calibration graph was constructed.
Method II (NEDA method). – Aliquots of the working standard solution of the drug
(1.0–5.0 mL) (100 mg mL–1) were transferred into 10-mL calibrated flasks. Hydrochloric
acid (0.2 mL, 11.3 mol L–1) was added, cooled in an ice bath and aqueous solution of
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NaNO2 (1.0 mL, 0.145 mol L–1) was added. The solutions were cooled to 0 °C and an
aqueous solution of ammonium sulfamate (0.5 mL, 8.8 ´ 10–2 mol L–1) was added and
stirred for 5 min. Then the aqueous solution of NEDA (1.0 mL, 8 ´ 10–3 mol L–1) was
added and made up to the mark with water. The solutions were mixed thoroughly and
the absorbance was measured at 567 nm against reagent blank and a calibration graph
was constructed.
Validation
The linearity, slope and the intercepts were calculated using the regression equa-
tion. Precision and accuracy of the proposed methods were tested by carrying out the
determination of eight replicates of pure and commercial samples of the drug, whose
concentration was within Beer’s law range. Values of the standard deviation (SD), rela-
tive standard deviation (RSD) and range of error at 95% confidence level were calculated
(17). The two methods have been applied to various pharmaceutical formulations and
recovery studies have been made by the standard-addition method.
Intra-day precision and intra-day error of the methods were assessed from the re-
sults of eight replicate analyses on the pure drug solution. The mean values and relative
standard deviation values for replicate analysis at three different concentration levels
were calculated.
Accuracy of the methods was determined by recovery studies via the standard-ad-
dition method.
The limit of detection (LOD) and limit of quantification (LOQ) were calculated ac-
cording to the current ICH guidelines (18) as the ratio of 3.3 and 10 standard deviation
of the blank (n = 7), respectively, and the slope of the calibration line.
Selectivity studies. – To check the interference 10 mg mL–1 CFZM was selected for the
MBTH method; for the NEDA method, 20 mg mL–1 CFZM was used. Before adding the
reagents, a known amount of the interfering substance was added and the reaction was
carried out for both methods. The extent of interference by various excipients that often
accompany pharmaceutical formulations are tabulated in Table I.
Assay of the drug in injection dosage forms
The content of ten to twenty vials (depending on the content per vial) were mixed
thoroughly. An amount of the powder equivalent to 100 mg of active component was
weighed into a 100-mL volumetric flask, about 60 mL of water was added and shaken
thoroughly for about 20 min. The volume was made up to the mark with water, shaken
and filtered using filter paper. The filtrate was diluted sequentially to get 100 mg mL–1 of
the drug.
RESULTS AND DISCUSSION
The methods are based on (i) the oxidative coupling reaction of the drug with 3-me-
thylbenzothiazolin-2-one hydrazone (MBTH) in the presence of ferric chloride in acidic
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medium, and (ii) the coupling reaction between the diazotized drug and N-(1-naph-
thyl)ethylenediamine dihydrochloride (NEDA) in aqueous medium.
Reaction products
The absorbance spectra of the bluish colored product (CFZM-MBTH) with lmax of
628 nm and that of the purple colored product (CFZM-NEDA) with lmax 567 nm are
shown in Fig. 1. The above mentioned blanks have practically negligible absorption in
both systems.
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Fig. 1. Absorbance spectra of
(CFZM-MBTH) and (CFZM-
-NEDA) reaction products (ini-
tial concentration of CFZM
was 10 and 20 mg mL–1, respe-
ctively).





Magnesium stearate 99.8 ± 0.4 99.4 ± 0.2
Lactose 99.5 ± 0.2 99.8 ± 0.7
Dextrose 99.9 ± 0.5 99.7 ± 0.1
Starch 99.9 ± 0.5 99.5 ± 0.3
Gum acacia 99.8 ± 0.3 100.0 ± 0.1
Talc 99.6 ± 0.4 99.8 ± 0.3
Carboxy methyl cellulose 99.6 ± 0.4 99.7 ± 0.1
Sodium alginate 99.7 ± 0.3 99.9 ± 0.3
a Amount: 40 mg.
b Mean ± SD, n = 5.
c Concentration ratio drug to excipient 1:400.
d Concentration ratio drug to excipient 1:200.
In the MBTH method, the drug reacts with MBTH in the presence of FeCl3 in acidic
medium to give a blue colored product. Actually, this is an iron catalyzed oxidative cou-
pling reaction of MBTH with the drug. Under the reaction conditions, on oxidation,
MBTH loses two electrons and one proton forming an electrophilic intermediate, which
is the active coupling species. This intermediate undergoes electrophilic substitution with
the drug to form the colored product. The NEDA method includes diazotization of the
drug to form diazonium salt, which on coupling with NEDA yields a purple azo dye. The
reaction mechanisms (CFZM-MBTH) and (CFZM-NEDA) for both methods are shown
in Schemes 1 and 2, respectively.
The colored products were found to be stable for 18 and 6 hours, respectively, at
room temperature. Reproducible results were obtained in the temperature range of
20–40 °C. An increase in temperature above 40 °C decreased the absorbance readings in
the NEDA method, indicating decomposition of the product.
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Optimization of reaction conditions
For the MBTH method, to achieve maximum color intensity 8.6 ´ 10–4 mol L–1
MBTH, 4.5 ´ 10–3 mol L–1 ferric chloride and 1 ´ 10–3 mol L–1 hydrochloric acid were
necessary.
For NEDA method, for the development of maximum color intensity 0.226 mol L–1
hydrochloric acid, 1.45 ´ 10–2 mol L–1 sodium nitrite, (4.4 ´ 10–3 mol L–1) ammonium sul-
famate and 8 ´ 10–4 mol L–1) NEDA were necessary. The excess of nitrite could be re-
moved by the addition of (4.4 ´ 10–3 mol L–1) ammonium sulfamate solution. An excess
of ammonium sulfamate has no effect on the color intensity of the product formed. In
the case of NEDA as a coupling agent, dilution of the colored solution with different sol-
vents like water, methanol, ethanol, acetic acid and acetonitrile was tested. However, di-
lution with water gave maximum intensity and stability of the color. Temperature of 30
°C is recommended for the absorbance measurements of colored products.
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Linear correlations were found between absorbance at lmax and CFZM concentra-
tion and are described by the regression equations:
A = 0.078 + 0.138 g; R = 0.9999, n = 8 (MBTH method)
A = 0.0199 + 0.00534 g, R = 0.9989, n = 8 (NEDA method)
where A is the absorbance and g is the concentration in mg mL–1, R is the correlation
coefficient and n is the number of measurement levels. Beer’s law is obeyed for 2–10 and
10–50 mg mL–1 for the MBTH and NEDA methods, respectively. Calculated apparent
molar absorptivity values were found to be 6.0 ´ 104 and 1.3 ´ 104 L mol–1 cm–1 for the
MBTH method and NEDA methods, respectively.
The LOD values were found to be 0.15 and 0.79 µg mL–1 for CFZM with MBTH and
with NEDA, respectively. The LOQ values were 0.50 and 2.61 µg mL–1 for CFZM with
MBTH and with NEDA, respectively. These values indicate that the MBTH method is
more sensitive than the NEDA method.
Table II summarizes the intra-day precision and intra-day error data for the assay of
CFZM in pure drug solution by the proposed methods. The intra-day RSD values ran-
ged from 0.1–0.4%, reflecting the usefulness of the method in routine use, and er data
was  2.0%.
The results of the selectivity study as shown in Table I confirm that the proposed
methods are accurate and precise even in the presence of various excipients. Amines such
as aniline, piperidine, morpholine, interfere in the NEDA method, because of the diazo-
tization reaction. It was found that in both methods, excipients like magnesium stearate,
lactose, dextrose, starch, gum acacia, talc, carboxymethyl cellulose and sodium alginate
in the concentration excess (1:400 and 1:200) over the drug do not interfere in MBTH and
NEDA methods, respectively. Recoveries of CFZM in selectivity testing were found to be
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er (%) RSD (%) CL (mg mL-1)
MBTH
0.5 0.49 0.8 0.4 0.49 ± 0.002
1.50 1.49 0.13 0.2 1.49 ± 0.002
2.50 2.49 0.1 0.2 2.49 ± 0.004
NEDA
3.0 2.99 0.15 0.1 2.99 ± 0.001
3.50 3.49 0.11 0.10 3.49 ± 0.003
4.00 3.99 0.25 0.1 3.99 ± 0.002
er – relative error.
CL – confidence limits at 95% confidence level for seven degrees of freedom.
99.7 ± 0.4 and 99.7 ± 0.3% for MBTH and NEDA methods, respectively, indicating selecti-
vity of both methods. Even precisionwise, the proposed methods are satisfactorily, with
low RSD values ranging from 0.1 to 0.7%.
Application to dosage forms
The proposed methods were applied to the analysis of CFZM in vials and the re-
sults were statistically compared with those obtained by the official HPLC method (7) by
calculating the Student’s t- and F-values. The evaluated t- and F-values were less than
the tabulated values at the 95% confidence level for seven degrees of freedom (18), as re-
vealed by the results complied in Table III. This actually suggests that the proposed me-
thods are accurate and precise as the official method (7).
In order to further ascertain the accuracy and reliability of the methods, recovery
experiments were performed by the standard-addition method. Pre-analyzed formula-
tion was spiked with pure CFZM at three different levels and the total was found by the
proposed methods. The percent recovery of pure drug added was in the range of
99.3–102.3% for MBTH and from 97.6–101.5% for NEDA. RSD ranged from 0.3 to 0.9%.
The results of this study summarized in Table IV indicate that neither the accuracy nor
the precision of the methods is affected by the coformulated substances.
The proposed methods are simple, rapid and reliable. In contrast to the charge
transfer complex method (6) reported earlier, the proposed methods are more sensitive,
with a range of 2–10 mg mL–1 (7.85 ´ 10–7–1.57 ´ 10–6 mol L–1), and can be applied to a
single vial so that vial to vial variation, if desirable, can be followed. Performance char-
acteristics of the existing spectrophotometric methods (15, 16) and the present methods
are compared in Table V, from which it is obviously clear that the proposed methods are
free from drastic experimental conditions such as heating or extraction unlike many re-
ported procedures. Both methods are highly sensitive compared to all the existing spec-
trophotometric methods, as shown by the molar absorptivity values and, in fact, the
method using MBTH is the most sensitive method ever reported for CFZM. The pro-
posed methods use eco-friendly and inexpensive chemicals and seldom employ organic
solvents.
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MBTH NEDA MBTH NEDA
1 250 99.8 ± 0.5 99.9 ± 0.4 99.9 ± 0.6 0.03 0.15 1.87 2.74
2 500 99.7 ± 0.3 99.9 ± 0.3 100.0 ± 0.4 1.70 0.24 1.41 1.98
3 1000 99.8 ± 0.4 99.9 ± 0.3 99.8 ± 0.6 0.44 0.21 2.03 3.17
a Mean ± SD, n = 8.
b Tabulated value at 95% confidence level is 2.365.
c Tabulated value at 95% confidence level is 3.79.
CONCLUSIONS
Ceftazidime has been assayed in dosage forms using visible spectrophotometry. Two
methods can be used to monitor the content uniformity of injections and purity of cefta-
zidime raw material. The methods could be considered for the determination of CFZM
in quality control laboratories.
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Table V. Comparison of spectrophotometric methods for ceftazidime assay




Pd(II)/SLS 330 3.0–60 mg mL–1 – 9
KMnO4 430.5 0.0–30 mg mL
–1 – 10
NBD-Cl 414 63.66–254.66 mg mL–1 – 12
Ammonium molybdate 716 2–70 mg mL–1 2.70 ´ 103 14
MBTH 628 2–10 µg mL–1 6.02 ´ 104 This paper
NEDA 567 10–50 µg mL–1 1.29 ´ 104 This paper
SLS – sodium lauryl sulfate
NBD-Cl – 4-chloro-7-nitrobenzofurazan
MBTH – 3-methylbenzothiazolin-2-one hydrazone
NEDA – N-(1-naphthyl)ethylenediamine dihydrochloride






















3.96 6.0 102.3 ± 0.3 2.96 5.0 99.6 ± 0.4
3.96 9.0 100.0 ± 0.4 2.96 10.0 100.3 ± 0.6
3.96 12.0 101.0 ± 0.4 2.96 15.0 101.1 ± 0.3
2
3.88 6.0 102.0 ± 0.8 3.07 5.0 99.4 ± 0.4
3.88 9.0 100.3 ± 0.6 3.07 10.0 100.5 ± 0.3
3.88 12.0 99.3 ± 0.7 3.07 15.0 101.5 ± 0.6
3
3.90 6.0 100.3 ± 0.4 2.96 5.0 97.6 ± 0.9
3.90 9.0 99.6 ± 0.8 2.96 10.0 99.7 ± 0.3
3.90 12.0 100.2 ± 0.3 2.96 15.0 100.8 ± 0.7
a Mean ± SD, n = 3.
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S A @ E T A K
Razvoj i validacija spektrofotometrijskih metoda za odre|ivanje
ceftazidima u farmaceutskim doziranim pripravcima
BASAVARAJ HIREMATH i BENNIKALLU HIRE MATHADA MRUTHYUNJAYASWAMY
Razvijene su dvije spektrofotometrijske metode za odre|ivanje ceftazidima (CFZM),
~istog ili u farmaceutskim pripravcima. Prva metoda se temelji na reakciji 3-metilbenzo-
tiazolin-2-on hidrazona (MBTH) sa ceftazidimom u prisutnosti `eljezovog(III) klorida u
kiselom mediju. Nastaje plavi kompleks s maksimumom apsorpcije pri lmax 628 nm.
Druga metoda se temelji na reakciji izme|u diazotiranog lijeka i N-(1-naftil)etilendiamin
dihidroklorida (NEDA), pri ~emu nastaje ljubi~asti produkt s lmax pri 567 nm. Reakcijski
uvjeti su optimirani da se dobije maksimalni intenzitet boje. Apsorbancija raste linearno
s pora{}u koncentracije CFZM; sustavi slijede Beerov zakon u koncentracijskom podru-
~ju 210 za MBTH metodu i 1050 µg mL1 za NEDA metodu. LOD i LOQ te vrijednosti
korelacijskog koeficijenta su 0,15, 0,79 i 0,50, 2,61. Uobi~ajene pomo}ne tvari ne smetaju
odre|ivanju ceftazidima. Predlo`ene metode su jednostavne, osjetljive, to~ne i pogodne
za primjenu u kontroli kvalitete.
Klju~ne rije~i: ceftazidim, diazotacija, spektrofotometrija, farmaceutski pripravak
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